AptarGroup, Inc. (ATR) Market Cap

AptarGroup, Inc. (ATR) has a market capitalization of $9.43B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Instruments & Supplies
Employees: 13000
Exchange: New York Stock Exchange
Headquarters: Crystal Lake, IL, US
Website: https://www.aptar.com

Loading company profile...

Expand full investment commentary ▼

📘 APTARGROUP INC (ATR) — Investment Overview

🧩 Business Model Overview

AptarGroup Inc. (ATR) is a global leader in the design and manufacturing of a broad array of dispensing, sealing, and drug delivery solutions for the pharmaceutical, beauty, personal care, home, and food & beverage industries. The company operates a diversified business model structured around providing critical packaging and delivery systems that facilitate controlled dispensing, enhance product safety, and ensure accurate dosage of consumer and healthcare products. Aptar leverages deep engineering, regulatory, and scientific expertise to co-develop and customize solutions in partnership with both consumer goods and pharmaceutical clients, embedding itself deeply in customer innovation cycles. Its global manufacturing footprint, with conveniently located sites close to major end-users, ensures robust supply continuity and high service levels.

💰 Revenue Streams & Monetisation Model

AptarGroup generates revenue through a combination of product sales, value-added customization, and, increasingly, services tied to regulatory support and testing for pharmaceutical delivery systems. The company’s revenue streams are diversified along both product and end-market lines: - **Pharmaceutical Systems:** A significant portion of sales arises from drug delivery solutions, such as nasal sprays, metered dose inhalers, eye care dropper systems, injectable device components, and connected digital health delivery systems. These products are often embedded within clients’ new drug launches, driving long product life cycles. - **Beauty & Personal Care:** Aptar supplies dispensing pumps, closures, aerosol valves, and custom packaging for global beauty and skincare brands, capturing value through proprietary designs and close integration in customer product development. - **Food & Beverage / Home:** Dispensing closures and systems for food, beverage, and household products form another leg of revenue, with products such as flip-top caps, valves, and tamper-evident solutions. - **Service & Value-Added Solutions:** The company provides regulatory consulting, analytical services, product prototyping, and efficacy/safety testing, increasingly capturing recurring revenues and deepening customer engagement beyond physical devices. The monetisation strategy revolves around manufacturing scale, premium pricing for regulatory and scientific rigor, customer-specific customization, and long-tail recurring demand as products remain on the market.

🧠 Competitive Advantages & Market Positioning

AptarGroup’s competitive moat rests on several intertwined factors: - **High Barriers to Entry:** Particularly in pharmaceutical packaging and delivery, regulators require rigorous validation and approval, giving established players like Aptar a clear edge. - **Deep Customer Integration:** The company regularly collaborates on long-term innovation processes with multinational customers, embedding designs from the earliest stages of product development and increasing switching costs. - **Global Scale and Diversification:** With manufacturing and R&D capabilities spread across North America, Europe, Asia, and Latin America, Aptar can cost-effectively serve global and regional customers while maintaining agility and redundancy against supply disruptions. - **Intellectual Property Portfolio:** Proprietary dosing, sealing, drug delivery technologies, and device designs bolster product differentiation and pricing power. - **Regulatory and Scientific Expertise:** Especially in healthcare, Aptar’s established working relationships with regulatory bodies and experience navigating strict compliance requirements are highly valued by clients. These advantages help position AptarGroup as a premium supplier within critical nodes of value chains for multiple industries, giving it stability, pricing resilience, and an opportunity to secure long-term customer relationships.

🚀 Multi-Year Growth Drivers

- **Healthcare and Rx Market Expansion:** The global pharmaceutical market’s secular growth, especially for biologics, generics, and chronic therapies requiring advanced delivery methods, directly supports Aptar’s healthcare segment. Elevated standards for safety, convenience, and patient compliance continue to drive upgrades in drug delivery. - **Consumer Demand for Convenience and Safety:** Trends in personal care, food, and household sectors — such as increased focus on product safety, user experience, and single-use convenience — sustain innovation in dispensing systems. - **Regulatory Evolution:** Stricter global regulations around drug and food packaging push brands toward high-quality, compliant solutions, favoring established players such as Aptar. - **Emerging Markets Penetration:** Growth of middle classes, urbanization, and westernization of consumption patterns in Asia, Latin America, and Africa increase demand for branded, premium packaging. - **Sustainability & Eco-Innovation:** Customer and regulatory pressures for recyclable, bio-based, and lightweight packaging drive new product pipelines. Aptar invests in sustainable materials and circular economy approaches, opening access to ESG-conscious clients and markets. - **Digital Health and Connected Devices:** The convergence of drug delivery and digital therapeutics (e.g., connected inhalers, smart injectors) creates new premium product categories, leveraging Aptar’s expertise in smart, sensor-enabled systems.

⚠ Risk Factors to Monitor

- **Customer Concentration:** A significant revenue share comes from relatively few global CPG and pharma customers, posing risks if large contracts are lost or brands insource packaging. - **Raw Material Volatility:** Fluctuations in resin and metal prices can pressure margins, though Aptar’s scale and ability to pass-through costs partially mitigates this risk. - **Regulatory Complexity:** Heightened global regulatory scrutiny in healthcare and food packaging could delay product launches and increase costs. - **Competitive Innovation:** Both established and niche competitors pursue R&D in materials science, digital health integration, and eco-design, requiring sustained Aptar investment to preserve technological leadership. - **Macro-Economic Sensitivity:** While healthcare end-markets offer some protection, consumer product packaging demand can be exposed to economic cycles and shifting consumer preferences.

📊 Valuation & Market View

AptarGroup is regarded by the market as a high-quality, defensive growth franchise, often trading at a valuation premium to broader packaging and industrial peers. Key factors contributing to this relative premium include the company’s exposure to resilient, innovative, and regulated end-markets, its consistent free cash flow generation, and strong return on invested capital. The company’s history of disciplined capital allocation—balancing organic investments, targeted M&A in adjacent technologies, and steady shareholder returns through dividends—further supports market confidence. Valuation multiples for Aptar have historically reflected its structural advantages and potential for secular top-line growth above GDP, partially offset by some sensitivity to raw materials prices and the cyclicality in non-healthcare segments. The company’s balanced capital structure, strong liquidity, and healthy balance sheet provide ample flexibility for continued investment and opportunistic acquisitions.

🔍 Investment Takeaway

AptarGroup Inc. stands out as a mission-critical partner across multiple global industries, leveraging science-driven innovation, regulatory expertise, and deep customer integration to anchor its competitive position. Multi-year structural tailwinds in pharmaceutical delivery, premium consumer product packaging, and sustainability position the company for sustained growth and margin resilience. While risk factors around raw material volatility, customer concentration, and competitive intensity merit ongoing attention, Aptar’s diversified revenue streams, robust innovation engine, and proven capital discipline offer a solid investment case for long-term oriented investors seeking exposure to defensive, innovation-led packaging and delivery markets.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

ATR Q4 2025 Earnings Summary

Overall summary: Aptar delivered strong Q4 top-line growth with all segments up on a core basis, led by Beauty and Injectables, and posted steady full-year progress. However, margins and EPS were pressured by mix, higher production costs, and emergency medicine declines. Management is addressing operational issues, advancing cost and centralization initiatives, and expects Beauty and Closures margin improvement as disruptions abate. Pharma’s pipeline and systemic nasal/injectables momentum remain robust, though a ~$65M emergency medicine headwind is expected in 2026. Capital returns were elevated, balance sheet remains strong, and long-term Pharma targets were reaffirmed.

Growth

  • Q4 reported sales up 14% to $963M; core sales up 5%
  • All three segments delivered core sales growth in Q4
  • Pharma core sales +4%; +10% excluding emergency medicine
  • Injectables core sales +24% on strong elastomeric component demand (GLP-1, antithrombotics, small molecules)
  • Consumer Healthcare core sales +3% (nasal decongestant, cough/cold)
  • Beauty core sales +10% (approx. 25% from tooling); Fragrance/Facial Skin/Color +7%; Personal Care +17%
  • Closures core sales +1%; Beverage +7% offsetting Food -1%
  • FY25 reported sales +5% to ~$3.8B; core sales +2%

Business development

  • FDA approval of Milestone’s CARDAMYST (self-administered Bidose nasal spray for PSVT) using Aptar’s device; U.S. launch expected Q1 2026
  • Exclusive agreement with Bausch + Lomb for Beat the Blink ophthalmic spray delivery system
  • CastleVax Phase II intranasal COVID-19 vaccine using Aptar’s LuerVax and Spray Divider platforms
  • Australia TGA approval of neffy (needle-free epinephrine nasal spray) utilizing Aptar technology
  • LTR Pharma initiated Phase II PK study of SPONTAN (intranasal ED therapy)
  • Unilever adopted high-dose all-plastic pumps for Nexxus hair care (NA); Chanel customized airless pump for HYDRA BEAUTY; Chinese brand launch with airless/reloadable solutions
  • Closures wins: McCormick’s Cholula Cremosa flip-top pour spout; Coca-Cola Powerade/BonAqua spout with tamper-evident tech (SA); Unilever PCR dosing closure for fabric softeners (Brazil)
  • Sustainability recognitions: CDP Climate A List; Newsweek America’s Most Responsible Companies (ranked 56/600)

Financials

  • Q4 adjusted EBITDA $191M (-2% YoY); margin 19.8% (down 320 bps YoY) on mix and higher production costs in Beauty/Closures
  • Q4 adjusted EPS $1.25 (down 23% YoY at comparable FX)
  • Q4 Pharma adj. EBITDA margin 32.4% (down 330 bps) on mix and lower emergency medicine
  • Q4 Beauty adj. EBITDA margin 10.2% (down 220 bps) impacted by low-margin tooling, environmental upgrades, and supplier transition costs
  • Q4 Closures adj. EBITDA margin 14.9% (down 120 bps) due to maintenance and higher low-margin tooling
  • Q4 gross margin down 371 bps YoY; SG&A 15.7% of sales (down 60 bps YoY); higher D&A and interest expense
  • Record Q4 tooling sales; FY25 second-highest tooling sales in over a decade
  • FY25 adjusted EBITDA margin 21.6% (flat YoY); adjusted EPS $5.74 (-1% at comparable FX); reported EPS $5.89 (+7%)
  • FY25 free cash flow $303M (CFO $570M; capex net $267M); cash/ST investments $410M; net debt ~$1.1B; leverage 1.38x
  • Adjusted effective tax rate: Q4 19.4% (vs 13.5% prior on one-off), FY25 21.4% (vs 20.5%)

Capital & funding

  • Issued $600M of 4.75% senior notes due March 2031 (unsecured)
  • Repurchased $175M of shares in Q4; $365M for FY25 (highest in a decade)
  • Returned $486M to shareholders in FY25 (repurchases + dividends)
  • New $600M share repurchase authorization (replaces prior)
  • Capex ~7% of sales in FY25; reduced YoY with focus on high-return projects
  • 32nd consecutive year of increasing annual dividend

Operations & strategy

  • Accelerating cost reduction and back-office centralization through global talent centers
  • Addressing operational disruptions: environmental upgrades at metal anodization plant; supplier requalification and added quality testing in Beauty; equipment maintenance in Closures (transitory)
  • Expect steady, quarterly improvement in Beauty margins through H1 2026; Closures maintenance issues expected to abate
  • Pharma long-term target: 7%–11% core sales growth and 32%–36% adjusted margins
  • High tooling activity supports customer retention and future wins
  • Ongoing productivity initiatives to counter cost inflation and mix headwinds

Market & outlook

  • Customer holiday sell-through (e.g., 11/11 China, U.S. Black Friday) reported as encouraging for Beauty end-markets
  • Systemic nasal drug delivery accelerating; injectables an increasing share of Pharma pipeline
  • Pharma revenue historically ~90% repeat business, ~10% pipeline contribution
  • Emergency medicine expected to be a ~$65M revenue headwind in 2026; more pronounced in H1 with moderation in H2 comparisons; expected margin pressure due to high-value mix
  • Closures volumes improving; resin pass-through dampening core sales
  • Management focused on productivity and efficiency in 2026; expecting margin normalization as disruptions recede

Risks & headwinds

  • Significant decline in emergency medicine demand and funding dynamics through 2026
  • Higher-than-expected production costs and operational disruptions in Beauty and Closures
  • Lower-margin mix (notably high tooling) weighing on gross margin
  • Supplier transition and environmental compliance upgrades increasing near-term costs
  • Maintenance-related production impacts in Closures
  • Higher interest expense and D&A; currency effects; elevated tax rate versus prior-year one-off benefit
  • Resin price pass-through reducing reported core sales in Closures

Sentiment: mixed

📊 AptarGroup, Inc. (ATR) — AI Scoring Summary

📊 AI Stock Rating — Summary

AptarGroup reported quarterly revenue of $962.7 million with a net income of $74.3 million, resulting in an EPS of $1.14. The net margin stood at 7.7%, and the company recorded a free cash flow of $96.9 million. Year-over-year revenue growth remains modest without reference data, but targeting an efficient cost structure has helped maintain profitability. The strong free cash flow supports consistent dividend payments and strategic stock buybacks, enhancing shareholder value. Aptar's total assets of $5.25 billion compare against $2.54 billion in total liabilities, giving a healthy equity cushion of $2.71 billion and a net debt of $737 million. The financial position reflects sound leverage with a focus on debt reduction and robust cash holdings of $402 million. Analyst sentiment indicates a consensus price target of $166, with a historical dividend yield corroborating continued investment in growth and shareholder returns.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue growth appears stable, supported by market demand though specific growth rate details were not provided.

Profitability — Score: 8/10

Profit margins and EPS demonstrate strong operational efficiency and continued profitability improvements.

Cash Flow Quality — Score: 7/10

Free cash flow is solid, supporting dividends and strategic buybacks, reflecting good management of cash resources.

Leverage & Balance Sheet — Score: 7/10

A balanced financial structure with healthy equity, effective debt management, and adequate liquidity positions.

Shareholder Returns — Score: 8/10

Continued dividends and buybacks underline commitment to shareholder value, complemented by stock performance targets.

Analyst Sentiment & Valuation — Score: 6/10

Consensus price target suggests moderate upside potential, balanced by current valuation metrics.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

MASI logo

MASIMO CORP (MASI)

Healthcare

$9.42B

TECH logo

BIO TECHNE CORP (TECH)

Healthcare

$9.23B

IBRX logo

IMMUNITYBIO INC (IBRX)

Healthcare

$9.63B

TEM logo

TEMPUS AI INC CLASS A (TEM)

Healthcare

$9.20B

MDGL logo

MADRIGAL PHARMACEUTICALS INC (MDGL)

Healthcare

$9.81B

HSIC logo

HENRY SCHEIN INC (HSIC)

Healthcare

$9.99B